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The publication of the crystal structures of a bacterial quorum sensing receptor complexed with a variety of
ligands (Zou and Nair, 2009) provides a much-needed molecular rationale for the modulation of this intercel-
lular signaling process, which may facilitate the development of new therapeutic agents.Many species of bacteria employ a mech-
anism of cell-cell communication known
as quorum sensing. This signaling pro-
cess, mediated by small molecules
(termed autoinducers) is used by bacterial
colonies to coordinate gene expression in
a cell density-dependent manner (Fuqua
et al., 1994). Several clinically relevant
pathogens use quorum-sensing systems
to regulate processes associated with
virulence. However, quorum sensing is
not directly involved in biological pro-
cesses that are essential for bacterial
survival (Rasmussen and Givskov, 2006).
Thus, selective disruption of quorum
sensing using nonnative small molecule
entities represents a strategy to attenuate
bacterial pathogenicity without imposing
an intense selective pressure for the
development of resistant mutants (Amer
et al., 2008; Kapadnis et al., 2009). Zou
and Nair (2009) now describe crystal
structures of a Pseudomonas aeruginosa
quorum-sensing receptor protein LasR
bound to various small molecule quorum-
sensingagonists.Thisworkmarksasignif-
icant advancement in our understanding
of the molecular basis of quorum sensing
in this bacterium. It reveals the funda-
mental information about bonding interac-
tions between the receptor and small
molecules that are necessary for modula-
tion of this communication system. Such
insights may allow the rational design of
inhibitors to target the quorum-sensing
pathway in this clinically relevant path-
ogen, with possible therapeutic applica-
tions in the treatment of human bacterial
infections.
P. aeruginosa is an opportunistic hu-
man pathogen that is involved in a range
of life-threatening nosocomial infections
and is also the primary cause of mortality
in cystic fibrosis sufferers (Rasmussenand Givskov, 2006). The virulence of this
bacterium is regulated by a complex
quorum-sensing signaling cascade that
utilizes numerous signaling molecules,
most notablyN-3-oxo-dodecanoyl homo-
serine lactone (OdDHL) (Figure 1). The
binding of OdDHL to the bacterial sig-
naling receptor LasR results in the tran-
scription of most genes that are associ-
ated with the progression of infection
and resistance to the host immune sys-
tem (Zou and Nair, 2009; Welch et al.,
2005). It is therefore unsurprising that
intense research efforts have been di-
rected toward the discovery of small
molecules that can bind to LasR and
thereby modulate this quorum-sensing
pathway (Geske et al., 2008; Lee et al.,
2008; Glansdorp et al., 2004).
Small molecule agents capable of
modulating the LasR quorum-sensing
system have typically been discovered
through a design and synthesis process,
using the structure of the known agonist
OdDHL as a template. However, such
a rational design approach is complicated
by the fact that LasR shows a very high
specificity for its cognate autoinducer
OdDHL. For example, the autoinducer
OOHL (N-3-oxo-octanoyl homoserine
lactone) with a related signaling receptor
TraR is structurally identical to OdDHL,
except that the acyl chain is four carbon
atoms shorter. However, despite the
structural similarity, OOHL does not in-
teract with the LasR receptor (Zou and
Nair, 2009). Thus, there are significant
structural constraints placed upon any
nonnative small molecule modulators of
LasR, which are based on the homoserine
lactone scaffold, with little deviation from
the parent framework apparently toler-
ated. In addition, there are problems
associated with any pharmaceuticalChemistry & Biology 16, September 25, 2009agent that incorporates a homoserine
lactone moiety; this structural feature is
unstable at alkaline pH and is readily
degraded by mammalian lactonases,
thus limiting the efficacy of any synthetic
derivatives (Glansdorp et al., 2004).
Consequently, the identification of new
classes of small molecule modulators of
LasR that are structurally distinct from
the homoserine lactone autoinducer is
an area of significant interest.
The high-throughput screening of small
molecule libraries has proven to be a valu-
able method for the discovery of quorum-
sensing modulators. Such an approach
was recently employed by Muh et al.
(2006a). This lead to the identification of
a triphenyl scaffold based compound
(TP-1), which was shown to be a potent
activator of LasR-dependent signaling,
despite the lack of any appreciable struc-
tural similarities to the LasR autoinducer
OdDHL (Figure 1). Further research estab-
lished that TP-1 and its derivatives TP-2,
TP-3, and TP-4 act directly through the
LasR receptor in a highly selective fashion
(Muh et al., 2006b). Zou and Nair (2009)
now report the high-resolution crystal
structures of the ligand-binding domain
of the LasR receptor in complex with the
triphenyl compounds TP-1, TP-3, and
TP-4. Analysis of these crystal structures
allows delineation of the process of
recognition of these novel compounds
by LasR at a molecular level, which may
allow a determination of the ensemble of
steric and electronic features required in
a ligand to ensure optimal and specific
interaction with the LasR receptor (Hajduk
and Greer, 2007). These results thus
provide a template for the rational design
of novel inhibitors, based around the tri-
phenyl scaffold (and perhaps other frame-
works) that target the quorum-sensingª2009 Elsevier Ltd All rights reserved 913
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Binding of OdDHL to the LasR receptor promotes receptor dimerization and the resultant homodimer
complex binds target DNA to activate gene transcription. The chemical structure of OdDHL is given,
together with OOHL, that acts via a different receptor protein. The structure of the nonnative TP-ligands
developed by Muh et al. (2006b) are also shown.signal pathway in pathogenic P. aerugi-
nosa. Furthermore, such information
could potentially be applied in fragment-
based approaches toward the discovery
of new LasR modulators, whereby
libraries of small fragment units each con-
taining structural motifs that are known to
be capable of high-affinity interaction with
the LasR receptor can be screened for
activity, thus providing good, low molec-
ular-weight starting points for a lead opti-
mization drug discovery program (Hajduk
and Greer, 2007).
In addition, the work of Zou and Nair
(2009) allows a molecular rationale for
understanding how structurally distinct
classes of compounds can interact with
the same highly selective receptor. This
should provide a framework for under-
standing more precisely the molecular
basis behind the activity of previously914 Chemistry & Biology 16, September 25,developed small molecule modulators of
LasR-dependent signaling. Such knowl-
edge may facilitate the deliberate rational
structural modification of such agents in
order to improve various molecular prop-
erties (e.g., efficacy and selectivity) with
the ultimate goal of developing an efficient
inhibitor of LasR that shows low toxicity to
humans. However, in this context, it is
worth noting that out of the five triphenyl
compounds that were identified, only
TP-5 was found to function as an antago-
nist, rather than an agonist, of LasR func-
tion. Unfortunately, Zou and Nair (2009)
report that the crystal structure of the
LasR-TP-5 complex could not be deter-
mined. Thus, while the binding mode of
TP-5 to LasR is expected to be similar to
that of the other triphenyl ligands due to
their structural similarities, there never-
theless remains the possibility that TP-52009 ª2009 Elsevier Ltd All rights reservedmay interact with LasR in an entirely
different manner. This raises the option
that the dictates of molecular recognition
of a LasR antagonist may be very different
to those of an angonist, which could have
significant implications in terms of rational
antagonist design; there thus remains
significant scope for further insights in
this area.
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